The demand for biological buffering agents continues to rise

Industry background: The biological buffer market is entering a period of rapid growth

In recent years, with the continuous expansion of the global biopharmaceutical industry, the continuous iteration of in vitro diagnostic (IVD) technology, and the increasing investment in life science research, the market demand for biological buffering agents, as the core chemical raw materials for maintaining pH stability in biological systems, is experiencing unprecedented rapid growth.

According to statistics, the market size of China's biological buffer industry has reached 2.357 billion yuan by 2025, a year-on-year increase of 7.97%. With the popularization of molecular diagnosis and immune detection technologies, the demand for high-end biological buffering agents such as HEPES, MOPS, TRIS continues to rise. The rapid development of cutting-edge fields such as cell and gene therapy (CGT) has also opened up new growth opportunities for the biological buffer market.

From a global perspective, the bio buffer market also maintains strong growth momentum. According to Marketresearch.biz report, the global market size of biological buffering agents is expected to grow from $754 million in 2022 to $1.859 billion in 2032. Another organization predicts that the global market size of biological buffering agents will exceed 1.09 billion US dollars by 2026, and is expected to exceed 2.18 billion US dollars by 2035.

In terms of segmented products, taking New Desheng's core product Tris as an example, the global Tris market is expected to grow from $770 million in 2025 to $950 million in 2026, and expand to $6.89 billion by 2035, with a compound annual growth rate of 24.65% from 2026 to 2035. The use of Tris as a buffering agent in drug formulation, bioprocessing, and molecular biology research continues to increase, and the demand for high-purity products is particularly strong.

Another core product, HEPES, also saw significant growth. According to QYResearch, the global HEPES market sales have reached 531 million yuan by 2025, and are expected to climb to 952 million yuan by 2032, with a compound annual growth rate of 8.8%. HEPES is widely used in fields such as cell culture and IVD reagents, and the market demand continues to release.

Domestic substitution accelerates, upstream raw material enterprises usher in strategic opportunities

It is worth noting that against the backdrop of increasing global geopolitical risks and growing emphasis on supply chain security, the domestic substitution process for biological buffering agents is accelerating comprehensively.

As the starting year of the 15th Five Year Plan, 2026 is accelerating the formation of a clear policy system to support domestic scientific research reagents. Beijing, Shanghai, Suzhou, Shenzhen and other places have explicitly included "domestication of biological reagents" in their local biopharmaceutical industry special plans. The 14th Five Year Plan for the Development of Bioeconomy lists buffer solutions as key consumables for research and development, and the country continues to increase support for upstream core raw materials in biomedicine.

Under the dual demands of supply chain security and cost reduction and efficiency improvement, domestic biopharmaceutical and IVD enterprises are accelerating the introduction of high-quality local suppliers. The core raw materials upstream of the in vitro diagnostic industry chain, including diagnostic enzymes, antigens/antibodies, biological buffering agents, chemical raw materials, etc., are accelerating the breakthrough of import dependence.

New Desheng: Deeply cultivating IVD core raw materials and embracing market opportunities with a full range of product layouts

Since its establishment, Hubei Xindesheng Material Technology Co., Ltd. has always focused on the field of IVD reagent raw materials, deeply cultivating the research and development, production, and sales of core products such as blood vessel additives, biological buffering agents, chemiluminescence reagents, colorimetric reagents, enzyme preparations, etc.

In the biological buffering agent sector, Xindesheng has formed a matrix of more than 50 products represented by Tris, HEPES, MOPS, Bicine, Caps, Taps, EPPS, PIPES, etc., with a stable purity of over 99%, and can customize indicators according to customer application scenarios. The company's daily production can reach 5 tons, with an annual output of 2000 tons, which can meet the full cycle raw material needs of IVD enterprises from research and development to mass production.

In terms of product quality, Xindesheng strictly organizes production according to the ISO 9001 quality management system, with batch differences controlled within 1%. The products are widely used in high-end application scenarios such as in vitro diagnostic kits, cell culture media, and biopharmaceuticals.

In addition to biological buffering agents, Xindesheng has also developed a series of chemiluminescence reagents represented by acridine ester and luminol, a series of chromogenic substrates represented by TOOS and MAOS, and a blood sample pretreatment product system represented by heparin lithium, heparin sodium, EDTA dipotassium, tripotassium, and serum separation gel, providing one-stop services from raw materials to solutions for IVD enterprises.

With the continuous expansion of the Chinese biological buffer market and the deepening of the domestic substitution process for IVD core raw materials, Xindesheng will continue to leverage its technological advantages in chemical synthesis and large-scale production, continuously optimize product quality, enrich product pipelines, and provide high-purity, high batch consistency, and cost-effective core raw material guarantees for domestic and foreign IVD and biopharmaceutical enterprises.

Recent developments of the company can be followed: the orderly promotion of the construction of Huanggang new production base, and the gradual realization of stable mass production of enzyme products such as amylase substrates. Welcome new and old customers and partners to call or write to discuss cooperation.